T1	Participants 67 131	patients with type 2 diabetes and high-normal body lead burdens.
T2	Participants 164 188	type 2 diabetic patients
T3	Participants 575 698	University medical center; 50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (≥80-<600 μg)
T4	Participants 1396 1437	for Chinese patients with type 2 diabetes
T5	Participants 1939 1953	control group.
T6	Participants 1954 2022	17 (68%) control-group patients and 9 (36%) treatment-group patients
T7	Participants 2198 2264	nephropathy in type 2 diabetic patients with high-normal body lead
